MBQ-167 is under clinical development by MBQ Pharma and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MBQ-167’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MBQ-167 is under development for the treatment of triple negative breast cancer and gastric cancer. It is a 1,5-disubstituted 1,2,3-triazole derivative. It is administrated by oral route. The drug candidate acts by targeting Rac and cell division control protein 42 Homolog (CDC42).
For a complete picture of MBQ-167’s drug-specific PTSR and LoA scores, buy the report here.